Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of tucatinib + trastuzumab + capecitabine in HER2-positive metastatic breast cancer (Japan)
jRCT2051200152Phase 2Active, not recruiting
- Sponsor
- Seagen Inc.
- Start
- Apr 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tucatinib in breast cancer, sponsored by Seagen Inc. Primary endpoint: Objective response rate (ORR) in Japanese population. Started Apr 2021; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2051200152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200152.